These are the stocks posting the largest moves before the bell.Market Insiderread more
May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
Analyst Michael Olson says he has "a high degree of confidence" that Amazon shares can reach the level without "significant changes to the business."Investingread more
Special counsel Robert Mueller wants to talk to Congress about his investigation into the Trump campaign and Russian interference in the 2016 election, but he wants to do it...Politicsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Breaking up the social network won't lead to better data protection, said former Facebook executive Chris Kelly.Technologyread more
A downgrade from BMO analysts led to an unsavory drop in Chipotle's stock, and some analysts are advising waiting out the weakness.Trading Nationread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
Sears opens its first Home & Life stores and plans to open more as it looks for a fresh start after bankruptcy.Retailread more
New orders for U.S.-made capital goods fell more than expected in April, further evidence that manufacturing and the broader economy were slowing.Economyread more
China denounced U.S. Secretary of State Mike Pompeo for fabricating rumors after he said the chief executive of China's Huawei was lying about his company's ties to the...World Politicsread more
Valeant Pharmaceuticals International shares plummeted 18 percent Monday after the embattled drugmaker said it faces a previously undisclosed probe from the U.S. Securities and Exchange Commission.
Valeant said it received a subpoena from the SEC in the fourth quarter. The company has delayed its annual report with the SEC, and said it would have disclosed the probe in the filing if it had already been released.
The investigation is separate from a previous probe into Valeant's 2015 purchase of Salix Pharmaceuticals, according to Bloomberg, which first reported the news.
The investigation deals another blow to Valeant, which continues to face probes from two U.S. Attorneys and Congress. The drugmaker's shares have fallen 35 percent this year.
Valeant on Sunday canceled the release of its fourth-quarter results, previously set for Monday, and withdrew its 2016 financial guidance. The company announced that CEO Michael Pearson will return from medical leave effective immediately.
Valeant said it planned to release preliminary fourth-quarter results and 2016 outlook "in the near-term."